Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash & Current Investments (2020 - 2025)

Historic Cash & Current Investments for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $375.5 million.

  • Mirum Pharmaceuticals' Cash & Current Investments rose 3202.83% to $375.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $375.5 million, marking a year-over-year increase of 3202.83%. This contributed to the annual value of $280.3 million for FY2024, which is 209.94% down from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Cash & Current Investments is $375.5 million, which was up 3202.83% from $304.6 million recorded in Q2 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Cash & Current Investments peaked at $434.9 million during Q3 2022, and registered a low of $132.1 million during Q1 2023.
  • In the last 5 years, Mirum Pharmaceuticals' Cash & Current Investments had a median value of $294.7 million in 2022 and averaged $297.5 million.
  • In the last 5 years, Mirum Pharmaceuticals' Cash & Current Investments tumbled by 6040.22% in 2023 and then skyrocketed by 12929.97% in 2024.
  • Over the past 5 years, Mirum Pharmaceuticals' Cash & Current Investments (Quarter) stood at $256.5 million in 2021, then decreased by 1.88% to $251.7 million in 2022, then grew by 13.75% to $286.3 million in 2023, then dropped by 2.1% to $280.3 million in 2024, then surged by 33.97% to $375.5 million in 2025.
  • Its last three reported values are $375.5 million in Q3 2025, $304.6 million for Q2 2025, and $277.7 million during Q1 2025.